Recent Quotes
My Watchlist
Indicators
Hydroworld Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DexCom, Inc. - Common Stock (NQ:DXCM)

60.43 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DexCom, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
Johnson Fistel has Commenced an Investigation on Behalf of DexCom, Inc. Shareholders
From Johnson Fistel, PLLP
Via Business Wire
DEXCOM ALERT: Bragar Eagel & Squire, P.C. is Investigating DexCom, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Tariffs, Trump, and Turmoil
Via The Motley Fool
Topics Economy Government World Trade
What Does the Market Think About DexCom?
 
Via Benzinga
10 Worst Performing Large-Caps Last 12 Months
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Topics Stocks / Equities
What's going on in today's session: S&P500 movers
Stay updated with the movements of the S&P500 index in the middle of the day on Thursday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
FDA Approves Dexcom's 15-Day Wearable Glucose Management System. Company Plans US Launch
Dexcom G7 15-Day CGM approved by FDA for adults with diabetes; U.S. launch set for late 2025 with extended wear and advanced tracking features. 
Via Benzinga
2 Growth Stocks to Buy in the Tariff-Fueled Market Correction
Via The Motley Fool
Topics Artificial Intelligence Economy Government
PriceSmart Posts Better-Than-Expected Earnings, Joins Enact Holdings, DexCom And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
Dexcom Surges After FDA Clears Its Next-Generation Diabetes Device
Dexcom stock surged Thursday after the FDA cleared its newest diabetes device for an extended 15-day wear time. 
Via Investor's Business Daily
Topics Government Stocks World Trade
Dexcom G7 15 Day Receives FDA Clearance: the Longest Lasting Wearable and Most Accurate CGM System
From DexCom, Inc.
Via Business Wire
What 6 Analyst Ratings Have To Say About DexCom
 
Via Benzinga
Q4 Patient Monitoring Earnings Review: First Prize Goes to Masimo (NASDAQ:MASI)
Let’s dig into the relative performance of Masimo (NASDAQ:MASI) and its peers as we unravel the now-completed Q4 patient monitoring earnings season. 
Via StockStory
Topics Artificial Intelligence
Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry
Trump's 10% global tariff spares pharmaceuticals but impacts medical devices, with diabetes device makers facing the greatest strain. Large biopharma firms remain protected, while medtech companies... 
Via Benzinga
Topics Government World Trade
Dexcom Schedules First Quarter 2025 Earnings Release and Conference Call for May 1, 2025 at 4:30 p.m. Eastern Time.
From DexCom, Inc.
Via Business Wire
Q4 Earnings Highlights: iRhythm (NASDAQ:IRTC) Vs The Rest Of The Patient Monitoring Stocks
Looking back on patient monitoring stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including iRhythm (NASDAQ:IRTC) and its peers. 
Via StockStory
Topics Artificial Intelligence
10 Worst Performing Large-Caps Last 12 Months
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Topics Stocks / Equities
The Future of Healthcare: 10 Predictions For The Next Decade
The healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we... 
Via MarketMinute
Topics Artificial Intelligence
Dexcom Appoints Jon Coleman as Chief Commercial Officer
From DexCom, Inc.
Via Business Wire
Tuesday's session: top gainers and losers in the S&P500 index
Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Tuesday. 
Via Chartmill
Why DEXCOM INC (NASDAQ:DXCM) Is a Standout High-Growth Stock in a Consolidation Phase.
Based on a technical and fundamental analysis of NASDAQ:DXCM we ask: Is DEXCOM INC (NASDAQ:DXCM) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
DexCom (DXCM): 3 Reasons We Love This Stock
Over the past six months, DexCom has been a great trade. While the S&P 500 was flat, the stock price has climbed by 8% to $74.17 per share. This run-up might have investors contemplating their next... 
Via StockStory
Topics Stocks
Is DexCom Gaining or Losing Market Support?
 
Via Benzinga
Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers
Let’s dig into the relative performance of Insulet (NASDAQ:PODD) and its peers as we unravel the now-completed Q4 patient monitoring earnings season. 
Via StockStory
Topics Artificial Intelligence
Exploring the top movers within the S&P500 index during today's session.
Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Top S&P500 movers in Thursday's session
Let's have a look at what is happening on the US markets in the middle of the day on Thursday. Below you can find the top S&P500 gainers and losers in today's session. 
Via Chartmill
Nasdaq Sell-Off: 2 Brilliant Stocks to Buy No Matter What the Market Does Next
Via The Motley Fool
Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medication for Future of Type 2 Care
From DexCom, Inc.
Via Business Wire
10 Worst Performing Large-Caps Last 12 Months
Here’s this week’s top 10 worst performing Large-Caps in the last twelve months. 
Via Talk Markets
Topics Stocks / Equities
Patient Monitoring Stocks Q4 Results: Benchmarking ResMed (NYSE:RMD)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how ResMed (NYSE:RMD) and the rest... 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
40 41 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.